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Edited by Hans-Dieter KlenkAbstract Human neutrophil a-defensin 4 (HNP4) is more eﬀec-
tive than HNP1–3 in protecting human peripheral blood mono-
nuclear cells from infection by both X4 and R5 HIV-1 strains.
HNP4 binds to both CD4 and gp120 approximately two orders
of magnitude weaker than does HNP1, and is less eﬀectively
sequestered by glycosylated serum proteins than HNP1. These
results suggest that the HIV-1 inhibition by HNP4 stems at least
partially from a unique and lectin-independent property of
HNP4 with CD4 and/or gp120. Our ﬁnding identiﬁes an anti-
HIV-1 property of HNP4 and may have implications in the
development of new antiviral agents for AIDS therapy.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The ability of cationic antimicrobial peptides/proteins to
inactivate a broad range of microorganisms by disrupting their
cytoplasmic membranes constitutes an eﬀective innate defense
mechanism used by higher eukaryotes [1]. Among the most
extensively studied antimicrobial proteins are human defensins
– a class of cationic and Cys-rich proteins of 3–5 kDa ex-
pressed predominantly in leukocytes and epithelial cells [2,3].
On the basis of sequence homology and disulﬁde connectivity,
human defensins are classiﬁed into a- and b-families, both
adopting a similar core structure of a three-stranded b-sheet
stabilized by three intra-molecular disulﬁde bridges [4–6]. In
addition to functioning in the innate immune system as antimi-
crobial and antiviral eﬀector molecules, recent studies show
that human defensins promote adaptive immunity by mobiliz-
ing and/or activating certain types of immune cells through
receptor-mediated signaling pathways [7–10].
To date, six a-defensins have been identiﬁed in humans.
Four of these, known as human neutrophil peptide (HNP)
1–4, are present mainly in neutrophils [11–13]. Direct inactiva-
tion of various viruses by HNP1–3 was ﬁrst reported by Lehrer
and colleagues in 1986 [14]. Nakashima et al. [15] demon-
strated in 1993 that mammalian a-defensins also inhibit hu-*Corresponding author. Fax: +1 410 706 7583.
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vitro – a ﬁnding conﬁrmed independently by several other lab-
oratories with HNP1–3 [16–18]. Recently, a family of 18-resi-
due macrocyclic, tridisulﬁde antibiotic peptides, termed h-
defensins, was identiﬁed in the leukocytes and bone marrow
of rhesus monkeys [19,20]. The putative hominid homolog of
rhesus monkey h-defensins, termed retrocyclin, is a lectin en-
coded by a pseudogene [21]. Retrocyclin protects human
CD4(+) T cells from infection by T- and M-tropic strains of
HIV-1 through binding to the sugar moieties on CD4 and
the viral envelope glycoprotein gp120 and inhibiting viral entry
[22,23]. However, the molecular mechanism for HIV-1 inhibi-
tion by HNPs remains to be deﬁned.
HNP1–3, diﬀering from each other by a single amino acid
residue at the N-terminus, account for 5–7% of the total neu-
trophil protein [24]. In contrast, the distantly related HNP4 is
much less abundant in neutrophils [11,13]. To date, little is
known about this fourth member of the a-defensin family,
due in large part to the relative scarcity of the native peptide,
and the lack of alternative means of producing it. We have
recently developed a robust synthetic approach to, and an
eﬃcient folding protocol for, the production of all human a-
defensins in high purity and yield [25–27], enabling for the ﬁrst
time comparative studies of these multi-functional proteins.
Here, we report that synthetic HNP4 is more eﬀective than
HNP1–3 in protecting human peripheral blood mononuclear
cells (PBMC) from infection by both X4 and R5 HIV-1 strains.
Our ﬁnding identiﬁes an antiviral property of HNP4, which
may have relevance toward the development of new anti-
HIV-1 agents for AIDS therapy.2. Materials and methods
2.1. Synthesis of HNP1–4
Solid phase peptide synthesis, folding and characterization of
HNP1–3 were previously described [26]. The preparation of highly
pure HNP4 was reported elsewhere [27]. The correct folding of syn-
thetic HNP4 was veriﬁed by determination of its three-dimensional
structure at 2.0 A˚ resolution by X-ray crystallography (unpublished re-
sults). Proteins were quantiﬁed by UV absorbance measurements at
280 nm based on molar extinction coeﬃcients calculated using the pub-
lished algorithm [28]. Synthetic HNP1–4 were dissolved at 1 mg/ml in
water and stored at 20 C. The sequences of HNP1–4 are as follows:
ACYCRIPACIAGERRYGTCIYQGRLWAFCC (HNP1, 30 aa,+3)
CYCRIPACIAGERRYGTCIYQGRLWAFCC (HNP2, 29 aa, +3)
DCYCRIPACIAGERRYGTCIYQGRLWAFCC (HNP3, 30 aa, +2)
VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRV (HNP4, 33 aa,
+4).blished by Elsevier B.V. All rights reserved.
Z. Wu et al. / FEBS Letters 579 (2005) 162–166 1632.2. Anti-HIV-1 assays
PBMC freshly prepared by Ficoll–Paque density gradient centrifu-
gation were grown in complete RPMI medium: RPMI 1640 supple-
mented with 10% heat inactivated fetal calf serum (FCS), 100 lg/
ml streptomycin and 100 U/ml penicillin. After activation with 1
lg/ml phytohemagglutinin and 10 ng/ml IL-2 for 3 days, PBMC were
acutely infected with HIV-1 virus at a ratio of 1 · 105 cells to 1000
TCID50 (50% tissue culture infectious doses) for 1 h at 37 C (multi-
plicity of infection = 0.01). The cells were washed twice with PBS to
remove unabsorbed viruses, re-suspended in complete RPMI medium
containing IL-2 (10 ng/ml), and placed, in duplicate, into 96-well
plates (1 · 105 cells/well) containing varying concentrations of test
defensin in a total volume of 200 ll complete culture medium. After
48 h, the cells were fed by removing 20 ll of medium and replacing
with an equal volume of fresh defensin of the same quantity previ-
ously used in each well. The level of HIV-1 replication was measured
by HIV-1 p24 antigen-capture ELISA 5 days after the infection.
Medium alone was used as control. Percent infection was determined
as a function of HIV p24 release into the medium in sample wells
versus in control wells. The inhibitory activity is expressed as IC50,
i.e., the defensin concentration at which 50% of HIV-1 replication
is inhibited.2.3. Surface plasmon resonance
Recombinant HIV-1 gp120BaL was produced in human epithelial
cells (293 cells) and puriﬁed on a Galanthus nivalis agglutinin lectin
aﬃnity column by our in-house mQuant Facility at IHV. Recombi-
nant soluble CD4 was obtained from Biogen. Dissociation equilib-
rium constants (Kd) of HNP1 and HNP4 interacting with CD4
and gp120 were determined by surface plasmon resonance on a BIA-
core 3000 instrument. Recombinant sCD4 (800 lg/ml in 10 mM bo-
rate buﬀer containing 1 M NaCl, pH 8.5) and gp120 (10 lg/ml in 10
mM acetate buﬀer, pH 5.5), were covalently coupled to CM5 carbox-
ylated dextran chips using N-hydroxysuccinimide (NHS) and N-
ethyl-N 0-(3-diethylamino-propyl)carbodiimide chemistry. Uncoupled
NHS–ester groups were blocked with 1 M ethanolamine, and about
2000 resonance units (RUs) of gp120 and 1000 RUs of CD4 were
coupled to the sensor chip by this procedure. Kinetic analysis was
carried out at 25 C in 10 mM HEPES, 150 mM NaCl, 3 mM
EDTA, and 0.005% surfactant P20, pH 7.4. Diﬀerent concentrations
of defensin were injected at a ﬂow rate of 20 ll/min over each ﬂow
cell, and binding was experimentally determined by comparing the
number of RUs observed as a function of time to an activated
and blocked ﬂow cell containing no covalently bound CD4 or
gp120. Non-speciﬁc binding of defensins to the control ﬂow cell
was insigniﬁcant.2.4. Analytical size-exclusion chromatography
20 lg each of HNP1–4 was analyzed on an Agilent 1100 series
HPLC equipped with an Amersham SuperdexTM Peptide PE size-
exclusion column (7.5 · 300 mm) running at a ﬂow rate of 0.4 ml/
min at room temperature. Several diﬀerent types of mobile phase were
used: PBS, 25 mM phosphate (pH 7.0) containing 1 M or 8 M urea or
1 M sucrose, and 20% or 50% acetonitrile containing 0.1% triﬂuoro-
acetic acid (TFA).2.5. Evaluation of defensins binding to serum proteins
Diﬀerent concentrations of HNP1 and HNP4 (0, 5, 10, 20, and 40
lM) were incubated at room temperature for 10 min in a total vol-
ume of 250 ll of the following three media: RPMI, RPMI plus 1%
FCS, and RPMI plus 10% FCS. After centrifugation at 12000 rpm
for 15 min in Centricon (Millipore, MWCO 10000), 50 ll of ﬁltrate
was injected on an Agilent 1100 series analytical HPLC system
equipped with a Vydac narrowbore C18 reversed phase column (5
lm, 2.1 · 150 mm). A linear gradient of 5–65% acetonitrile containing
0.1% TFA was applied at a ﬂow rate of 0.3 ml/min at 40 C over 30
min. Free defensin in the ﬁltrate not retained by culture media and
the ﬁlter membrane was quantiﬁed by peak integration. Percent bind-
ing of HNP1 or HNP4 to serum proteins was calculated based on free
defensin found in the ﬁltrate of RPMI and of the FCS-containing
RPMI.3. Results and discussion
3.1. HNP4 inhibits HIV-1 infection in PBMC more eﬀectively
than HNP1–3
We tested HNP1–4 for their inhibition of two laboratory
isolates HIVIIIB (X4) and HIVBaL (R5) and two primary iso-
lates B703 (X4) and NSI03 (R5) in PBMC using our standard
assay protocols. The results of the anti-HIV-1 assays on
HNP1–4 are shown in Fig. 1. All four a-defensins inhibit their
susceptible HIV-1 strains in a dose-dependent manner, with
similar IC50 values for HNP1–3 in the range of 5–20 lM, com-
parable to the results previously published for native HNP1–3
with various HIV-1 isolates. However, in comparison with
HNP1–3, inhibition of both strains of HIV-1 by HNP4 was
noticeably stronger as evidenced by lower IC50 values (2–5
lM) and steeper and more complete inhibition curves.
Infection of HIV-1 is initiated by the viral envelope glycopro-
tein, gp120, interacting with the primary receptor CD4 ex-
pressed on the surface of target cells [29]. This event results in
a conformational change in gp120 and enables the CD4-bound
protein to further interact with HIV-1 coreceptors CXCR4 or
CCR5, depending on the strains of HIV-1 [30–32]. The corecep-
tor binding by gp120, in turn, triggers the membrane-embedded
HIV-1 gp41 to expose its fusion peptides, leading to direct
fusion of the viral and cellular membranes [33]. Blocking the
binding of gp120 to either CD4 or HIV-1 coreceptors ablates
viral entry and aﬀords an attractive strategy for the therapeutic
intervention of HIV-1 infection [34]. It has been shown that
retrocyclin, the putative hominid homolog of rhesus monkey
h-defensins, potently inhibits HIV-1 infection through binding
to the sugar moieties of gp120 and CD4, thus blocking the
critical virus–cell fusion step in HIV infection [21–23]. The
lectin-like sugar-binding property of retrocyclin has also been
demonstrated, using the surface plasmon resonance (SPR)
technique, with several other glycosylated proteins. In light of
these ﬁndings with retrocyclin, it might seem reasonable to as-
sume that HNP1–3, HNP4 and the various h-defensins all use a
similar mechanism of inhibition. However, the following data
suggest that this may not be the case.3.2. HNP4 is a signiﬁcantly weaker ligand of CD4 and HIV-1
gp120 as compared with HNP1–3
Using the SPR technique, we have demonstrated that syn-
thetic HNP1 and HNP4 indeed bind to both recombinant
gp120 and CD4 immobilized on optical sensor chips. As shown
in Fig. 2, the apparent Kd values for HNP1 deduced from the
binding kinetics with gp120 and CD4 are 12.2 and 5.3 nM,
respectively. In contrast, HNP4 is roughly two orders of mag-
nitude weaker with both proteins (gp120, 640 nM; CD4, 758
nM). How can this be reconciled with our ﬁnding that
HNP4 is a better inhibitor of HIV-1 infection in vitro?
There are at least two plausible explanations. First, HNP4
may bind to diﬀerent regions of CD4 and/or of gp120, thus
more eﬀectively inhibiting direct fusion of the viral and cellular
membranes. Direct evidence in support of this hypothesis came
from the observation that de-glycosylation of gp120 and CD4,
while completely abolishing the binding of HNP1, has little ef-
fect on the binding of HNP4 [35]. This ﬁnding suggests that
HNP1 strongly interacts with carbohydrate molecules on
gp120 and CD4, whereas HNP4 probably binds to non-glycos-
ylated regions of the proteins with reduced aﬃnity.
Fig. 1. Inhibition of two laboratory HIV-1 isolates, IIIB (X4) and BaL (R5), and two primary HIV-1 isolates, B703 (X4) and NSI03 (R5), in PBMC
by synthetic HNP 1–4. The data for HIV-1IIIB are averages of triplicate assays with HNP1 and HNP2, and of duplicate assays with HNP3 and
HNP4. The data for HIV-1BaL are averages of triplicate assays with HNP1–3, and of duplicate assays with HNP4. The data for HIV-1B703 are from a
single experiment. The data for HIV-1NSI03 are averages of triplicate experiments with HNP1–3, and from a singular measurement with HNP4.
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using an Amersham SuperdexTM Peptide PE column also sup-
ports the conclusion that HNP4 is a less eﬀective lectin as com-
pared with HNP1. When PBS or 25 mM phosphate buﬀer
containing 1 M urea, pH 7.0, was used as mobile phase,
HNP1–4 were permanently retained on the Superdex resin
made of highly cross-linked agarose covalently bound to dex-
tran, suggesting a strong tendency for defensins to bind poly-
saccharides. An increase in the concentration of urea or the
use of 1 M sucrose in the mobile phase had little impact on
the retention of HNP1–4 (data not shown). In the mobile
phase of 20% acetonitrile containing 0.1% TFA, while HNP4
eluted out at the position expected for proteins of its size,
HNP1–3 still strongly lagged beyond the solvent peak at 25
min (Fig. 3). The lagging of HNP1–3 signiﬁcantly improved
when the organic content in the mobile phase was increased
to 50% (data not shown). Thus, despite the fact that HNP4
is more positively charged than HNP1–3, its binding to the su-
gar-based column matrix is obviously weaker. The reduced
aﬃnity of HNP4 for the column matrix is unlikely a result
of extreme solvent conditions as defensins are known to be
resistant to chemical, heat and acid denaturation (unpublished
data). These results are consistent with our ﬁndings with
HNP1 and HNP4 interacting with CD4 and gp120.
Second, since the complete medium used in our in vitro
antiviral assays contains 10% FCS, the abundant glycopro-
teins present in the serum component of the medium maysequester HNP1 more eﬀectively due to its higher aﬃnity
for carbohydrates. This will result in a disparity in HIV-1
inhibitory activity caused by diﬀerent concentrations of free
defensin in the assay system. To evaluate the possibility, we
simulated binding of HNP1 and HNP4 to serum proteins
in the culture medium containing either 1% or 10% FCS.
RPMI without FCS was used as control. The results are
shown in Fig. 4. Although both HNP1 and HNP4 were
sequestered by serum proteins, in RPMI containing 1%
FCS, HNP-1 was bound to an approximately 4-fold greater
extent than was HNP4. Expectedly, when they were added
to RPMI containing 10% FCS, a greater fraction of both
proteins was bound. However, about 3-4-fold more HNP4,
again, remained unbound, relative to HNP1. If only unbound
defensins manifest antiviral activity, these ﬁndings suggest
that using 10% FCS in the antiviral assay system is at least
partially responsible for the disparity seen with HNP1 and
HNP4 in the inhibition of HIV-1 infection in PBMC,
although it remains unclear if the serum-binding factor alone
is suﬃcient to account for the entire diﬀerence in HIV-1
inhibitory activity between HNP1–3 and HNP4.
Recently, Wang et al. have shown, in a separate study of var-
ious defensins, that HNP4 is one order of magnitude weaker
than HNP1 in binding to recombinant gp120 or CD4 [35].
The diﬀerence (2–3 orders of magnitude) in binding aﬃnity be-
tween HNP1 and HNP4 became much more pronounced for
fetuin, a glycosylated protein found in abundance in FCS.
Fig. 2. Binding kinetics of synthetic HNP1 and HNP4 to immobilized recombinant gp120 and CD4 on Biacore 3000. The apparent Kd values
obtained from curve ﬁttings based on a 1:1 interaction mode are for the purpose of comparison only because the kinetic data deviate from the
mathematical model due to molecular complexities of the defensin-CD4 and –gp120 interactions.
Fig. 3. HNP 1–4 (20 lg each) on Amersham Superdex Peptide PE 7.5/
300 column at room temperature. 20% acetonitrile containing 0.1%
TFA was used as mobile phase at a ﬂow rate of 0.4 ml/min. The
multiple peaks displayed by HNP1–3, which are structurally homoge-
neous and chromatographically pure on reversed-phase HPLC, may
reﬂect diﬀerential binding characteristics of HNP1–3 on the chemically
heterogeneous column matrix.
Fig. 4. Simulated binding of HNP1 and HNP4 to 1% FCS and 10%
FCS in RPMI. Percent binding of HNP1 or HNP4 to serum proteins
was calculated based on free defensin found in the ﬁltrate of RPMI
and of the FCS-containing RPMI.
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of defensins to gp120. These results are consistent with our
ﬁndings on the properties of HNP1 and HNP4.In conclusion, human neutrophil a-defensin 4 is eﬀective in
vitro in protecting PBMC from HIV-1 infection. The inhibi-
tion stems at least in part from a unique and lectin-indepen-
166 Z. Wu et al. / FEBS Letters 579 (2005) 162–166dent property of HNP4 with CD4 and/or gp120, which ap-
pears diﬀerent from that of HNP1–3. Further studies are
needed to elucidate the molecular mechanism(s) whereby
HNP4 inhibits HIV-1, and to explain the structural and func-
tional bases for these diﬀerences.
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